Latest publications

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S et al. Lancet 2023 Nov 23

The effectiveness of antibacterial therapeutic clothing compared with non-antibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: A randomized controlled, observer-blind pragmatic trial (ABC trial). Ragamin A, Schappin R, De Graaf M, Tupker RA, Fieten KB, Van Mierlo MMF et al. Br J Dermatol 2023 Nov 04

Prevalence and healthcare usage of Chronic Urticaria in Primary Care: A Population-Based Study in The Netherlands. Soegiharto R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Br J Dermatol 2023 Oct 28

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al. N Engl J Med 2023 Oct 26; 389(17):1579-1589

Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. Boesjes CM, Van der Gang LF, Bakker DS, Ten Cate TA, Spekhorst LS, De Graaf M et al. JAMA Dermatol 2023 Nov 01; 159(11):1240-1247

Systemic anti-inflammatory treatment of atopic dermatitis during conception, pregnancy and breastfeeding: Interdisciplinary expert consensus in Northern Europe. Deleuran M, Dézfoulian B, Elberling J, Knutar I, Lapeere H, Lossius AH et al. J Eur Acad Dermatol Venereol 2023 Sep 13

A concept for integrated care pathways for atopic dermatitis-A GA LEN ADCARE initiative. Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C et al. Clin Transl Allergy 2023 Sep; 13(9):e12299

IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval. Dekkers C, Van der Wal MM, Van den Noort L, Bakker DS, De Bruin-Weller M, Van Wijk F et al. Clin Exp Allergy 2023 Nov; 53(11):1222-1225

Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps. Van der Rijst LP, Van Royen-Kerkhof A, Pasmans SGMA, Schappin R, De Bruin-Weller MS, De Graaf M et al. J Dermatolog Treat 2023 Dec; 34(1):2254567

Prognostic Factors for Long-term Aesthetic Outcome of Infantile Haemangioma Treated with Beta-blockers. Hermans MM, Pasmans SGMA, De Graaf M, Ragamin A, Mendels EJ, Breur JMPJ et al. Acta Derm Venereol 2023 Aug 30; 103:adv5286

Age and fast initial response predict omalizumab retreatment in chronic urticaria. Meertens MAJ, Luijf T, Van Lindonk EAM, Soegiharto R, Assil S, Alizadeh Aghdam M et al. J Allergy Clin Immunol Pract 2023 Nov; 11(11):3556-3558.e1

Correction to: Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma. Hermans MM, Rietman AB, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ et al. Eur J Pediatr 2023 Sep; 182(9):4285-4287

Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. Reich K, Silverberg JI, Papp KA, Deleuran M, Katoh N, Strober B et al. J Eur Acad Dermatol Venereol 2023 Oct; 37(10):2056-2066

A European-Japanese study on peach allergy: IgE to Pru p 7 associates with severity. Kallen EJJ, Revers A, Fernández-Rivas M, Asero R, Ballmer-Weber B, Barreales L et al. Allergy 2023 Sep; 78(9):2497-2509

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16. Thyssen JP, De Bruin-Weller M, Costanzo A, Grond S, Schuster C, Liu C et al. Adv Ther 2023 Aug; 40(8):3574-3587